FGF23 and cardiac hypertrophy: Currently, several studies have associated high plasma levels of FGF-23 with increased left ventricular mass (LVM), and consequently, with the degree of cardiac hypertrophy developed in the general population (Gutiérrez et al., 2008; Mirza et al., 2009; Seiler et al., 2011; Shibata et al., 2013; Agarwal et al., 2014; Kestenbaum et al., 2014; Masson et al., 2015; Panwar et al., 2015; Reindl et al., 2017; Silva et al., 2019; Cheng et al., 2020; Patel et al., 2020).